<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330783</url>
  </required_header>
  <id_info>
    <org_study_id>BCH-RCC-141201</org_study_id>
    <nct_id>NCT02330783</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients</brief_title>
  <official_title>A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no standard treatment in patients with renal cell carcinoma that was previously
      treated with VEGF targeted therapies and mTOR inhibitors.So investigators conducted a
      randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib
      versus sorafenib for the third-line treatment of patients with Metastatic renal cell
      carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapies targeting VEGF and mTOR signalling pathways represent standard first-line and
      second-line treatment options for patients with metastatic renal cell carcinoma. There is no
      standard treatment in patients with renal cell carcinoma that was previously treated with
      VEGF targeted therapies and mTOR inhibitors.To the best of the investigators knowledge, GOLD
      study is the first phase 3 trial in the third-line setting after both VEGF-inhibitor and
      mTOR-inhibitor drugs.From this study,Sorafenib may be option for the third-line treatment.The
      Best trial demonstrated that Bevacizumab/sorafenib had best efficacy in advance renal cancer
      canrcinoma and the VEGF/VEGFR co-inhibition strategy may warrant further investigation
      possibly with more selective VEGFR inhibitors.So investigators conducted a randomized,
      open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus
      sorafenib for the third-line treatment of patients with Metastatic renal cell carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress-free survival,PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment until 31 December 2017 cut of date</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival,OS</measure>
    <time_frame>3 years</time_frame>
    <description>Time from enrollment to the dates of death from any cause or last follow up reported between date of first patient enrollment until 31 December 2017 cut of date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events</measure>
    <time_frame>1 years</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab plus Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 400mg Bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)</description>
    <arm_group_label>Bevacizumab plus Sorafenib</arm_group_label>
    <other_name>Avstin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>400mg twice daily by oral of each 4-week cycle</description>
    <arm_group_label>Bevacizumab plus Sorafenib</arm_group_label>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years, ≤75 years, male or female

          -  Advanced renal cellcarcinoma is diagnosed histologically or pathologically

               -  1st line treatment of Sunitinib and 2nd line treatment of Everolimus and no more
                  systemic anti-angiogenesis targeted drug therapy

               -  Have at least one measurable tumor lesion (Response Evaluation Criteria In Solid
                  Tumors)

               -  Eastern Cooperative Oncology Group（ECOG) performance scale is 0 or 1

               -  The expected life span is ≥12 weeks

               -  No contraindications for chemotherapy, with enough liver function and renal
                  function and normal ECG recording Peripheral hemogram: neutrophil≥1.5×109/L,
                  Plt≥100×109/L, Hgb≥90g/L Renal function: serum creatinine≤1.5 folds the upper
                  limit of normal (ULN) For patients with non-metastatic liver dysfunction:alanine
                  aminotransferase and aspartate aminotransferase≤2.5 ULN, For patients with
                  metastatic liver dysfunction: alanine aminotransferase and aspartate
                  aminotransferase≤5 ULN

               -  The patients participate voluntarily and have signed the informed consent form

        Exclusion Criteria:

          -  Pregnant and lactating women, or female patients of child-bearing age without taking
             contraceptive measures

               -  Patients with severe acute infection without being controlled effectively or
                  having pyogenic and chronic infections with persistently unhealed wounds

               -  Past history of serious heart diseases, including: cardiac function
                  classification ≥NYHA class II, unstable angina pectoris, myocardial infarction,
                  arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or
                  digoxin), and uncontrolled hypertension

               -  Patients with a history of HIV infection or active phase of chronic hepatitis B/C

               -  negative imaging examination result 4 weeks prior to enrollment)

               -  Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs)

               -  A history of allogeneic organ transplantation

               -  Patients with evidence of hemorrhagic constitution or a past history of
                  hemorrhage

               -  Patients currently receiving renal dialysis

               -  Past or present concomitant tumors with the primary lesions or histological
                  characteristics different from the tumors evaluated in this study, excluding
                  other tumor cured longer than 3 years before enrollment

               -  Patients participating in other clinical trials simultaneously

               -  Other conditions unsatisfying the inclusion criteria in the investigator's
                  opinions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Guo, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinan Sheng, MD</last_name>
    <phone>0086-10-88196951</phone>
    <email>doctor_sheng@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Guo, MD,PHD</last_name>
    <phone>0086-10-88196317</phone>
    <email>guoj307@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen university cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangjian Zhou, MD</last_name>
      <phone>0086-20-87343088</phone>
      <email>zhoufj@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Fangjian Zhou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhisong He, MD</last_name>
      <phone>0086-10-83572211</phone>
      <email>wyj7074@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Zhisong He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinan Sheng, MD</last_name>
      <phone>0086-10-88196951</phone>
      <email>doctor_sheng@126.com</email>
    </contact>
    <investigator>
      <last_name>Jun Guo, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinan Sheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dingwei Ye, MD</last_name>
      <phone>0086-21-64175590</phone>
      <email>dwye@163.com</email>
    </contact>
    <investigator>
      <last_name>Dingwei Ye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://meetinglibrary.asco.org/content/107093-134</url>
    <description>The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC)</description>
  </link>
  <reference>
    <citation>Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17.</citation>
    <PMID>24556040</PMID>
  </reference>
  <reference>
    <citation>Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. Review.</citation>
    <PMID>17255307</PMID>
  </reference>
  <reference>
    <citation>Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363. Figg, William D [added].</citation>
    <PMID>18669456</PMID>
  </reference>
  <reference>
    <citation>Pal SK, Vogelzang NJ. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2013 Mar;11(3):146-55. Review.</citation>
    <PMID>23598982</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Guo</investigator_full_name>
    <investigator_title>Director of department of renal cancer and melanoma</investigator_title>
  </responsible_party>
  <keyword>Metastatic Renal Cell Carcinoma</keyword>
  <keyword>Third-line treatment</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

